2
项与 重组人促卵泡激素Fc融合蛋白(Therawisdom Biopharma) 相关的临床试验A Randomized, Double-blind, Placebo-controlled, Single Dose, Escalation, Phase I Clinical Trial to Evaluate the Safety and Tolerability of TWP-201 in Healthy Female Subjects
This study is a randomized, double-blind, placebo-controlled, single dose, escalation, phase I clinical trial to evaluate the safety and tolerability of recombinant human follicle stimulating hormone Fc fusion protein injection (TWP-201) in healthy female subjects. The objective of the trial is to evaluate the safety and tolerability of TWP-201 in healthy female subjects.
随机、双盲、安慰剂对照评价重组人促卵泡激素Fc融合蛋白注射液(TWP-201)在健康女性受试者中单次给药,剂量递增的安全性和耐受性Ⅰ期临床研究
主要目的
评价TWP-201在健康女性受试者中安全性和耐受性;
次要目的
评价TWP-201的药代动力学特征;
评价TWP-201的药效学特征;
评价TWP-201的免疫原性。
100 项与 重组人促卵泡激素Fc融合蛋白(Therawisdom Biopharma) 相关的临床结果
100 项与 重组人促卵泡激素Fc融合蛋白(Therawisdom Biopharma) 相关的转化医学
100 项与 重组人促卵泡激素Fc融合蛋白(Therawisdom Biopharma) 相关的专利(医药)
100 项与 重组人促卵泡激素Fc融合蛋白(Therawisdom Biopharma) 相关的药物交易